Trial Profile
A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Therapeutic Use
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 27 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
- 31 Mar 2014 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.